logo-loader
viewZacks Small-Cap Research

Zacks Small-Cap Research: Biotech IPOs outperformed in 2019, talks through 2020 drivers

Zacks Small-Cap Research Senior Biotechnology Analyst John Vandermosten sat down with Proactive at the BIO CEO & Investor Conference in New York. Vandermosten says while biotech IPOs outperformed in 2019, on the horizon, some concerns loom that may affect these companies such as the deadly coronavirus, and the current political landscape.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Anglo Pacific 'operating as normal' through uncertainty and has access to...

Anglo Pacific Group PLC's (LON:APF) (TSE:APY) Julian Treger tells Proactive London's Andrew Scott that relative to many other companies they're in a good position. ''We continue to operate as usual, everyone's working remotely and there hasn't been an enormous disruption to our business''....

43 minutes ago

2 min read